These highlights do not include all the information needed to use FOSRENOL safely and effectively. See full prescribing information for FOSRENOL.
FOSRENOL (lanthanum carbonate) Chewable Tablets
Initial U.S. Approval: 2004
RECENT MAJOR CHANGES
Contraindications (4) 4/2011
Warnings and Precautions, Gastrointestinal Adverse Effects (5.1) 4/2011
INDICATIONS AND USAGE
-
FOSRENOL is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). (1)
DOSAGE AND ADMINISTRATION
-
Take FOSRENOL with or immediately after food. (2)
-
The recommended initial total daily dose of FOSRENOL is 1500 mg. (2)
-
Titrate the dose every 2-3 weeks until an acceptable serum phosphate level is reached. Monitor serum phosphate levels as needed during dose titration and on a regular basis thereafter. (2)
-
Most patients required a total daily dose between 1500 mg and 3000 mg to reduce plasma phosphate levels to less than 6.0 mg/dL. (2)
-
In clinical studies of ESRD patients, FOSRENOL doses up to 4500 mg were eva luated. (2)
-
Chew tablets completely before swallowing. To aid in chewing, tablets may be crushed. Do not swallow intact tablets. (2)
DOSAGE FORMS AND STRENGTHS
-
Chewable Tablets: 500 mg, 750 mg, and 1000 mg. (<
